



Correction to: Evaluation of Cardiovascular Disease Risk in HIV-1–Infected Patients Treated with Darunavir

Magda Opsomer¹ · Dessislava Dimitrova² · Johan Verspeelt¹ · Amy Purrington³ · Abdul Mehbob⁴ · Scott Chavers² · Helen Pai⁵ · Simon Vanveggel¹ · Donghan Luo² · Kimberley Brown⁶ · Christiane Moecklinghoff⁷ · Richard E. Nettles⁶ · Katia Boven²

Published online: 6 August 2018
© The Author(s) 2018

Correction to: Drugs in R&D
<https://doi.org/10.1007/s40268-018-0238-8>

In the original publication of the article, Table 2 has been published incorrectly. The corrected Table 2 is shown below:

The original article can be found online at <https://doi.org/10.1007/s40268-018-0238-8>.

✉ Magda Opsomer
mopsomer@its.jnj.com

- ¹ Janssen Research and Development, Beerse, Belgium
- ² Janssen Research and Development, LLC, Titusville, NJ, USA
- ³ Janssen Research and Development, LLC, Horsham, PA, USA
- ⁴ Janssen-Cilag Ltd, High Wycombe, UK
- ⁵ Janssen Research and Development, LLC, Raritan, NJ, USA
- ⁶ Janssen Scientific Affairs, LLC, Titusville, NJ, USA
- ⁷ Janssen EMEA, Neuss, Germany

Table 2 Signal scores from FAERS (2016Q2): cardiovascular and cerebrovascular events

Event*	First-generation PIs											
	Indinavir			Nelfinavir			Ritonavir			Saquinavir		
	<i>n</i>	EBGM	EB05	<i>n</i>	EBGM	EB05	<i>n</i>	EBGM	EB05	<i>n</i>	EBGM	EB05
Carotid artery occlusion	1	0.966	0.213	NR	NR	NR	3	1.057	0.405	1	1.021	0.225
Carotid artery stenosis	9	3.523	2.003	2	1.097	0.347	4	1.008	0.436	1	0.765	0.169
Carotid artery thrombosis	2	1.535	0.486	NR	NR	NR	NR	NR	NR	NR	NR	NR
Coronary artery insufficiency	1	1.23	0.271	NR	NR	NR	NR	NR	NR	NR	NR	NR
Coronary artery occlusion	32	3.275	2.432	10	1.517	0.889	35	1.975	1.486	16	3.147	2.063
Coronary artery thrombosis	2	1.367	0.433	1	0.636	0.14	2	0.635	0.201	4	2.846	1.227
Coronary artery stenosis	5	1.959	0.922	11	4.151	2.488	16	2.405	1.576	4	1.998	0.864
Ischemic stroke	1	0.505	0.111	NR	NR	NR	6	0.627	0.315	NR	NR	NR
Sudden cardiac death	NR	NR	NR	NR	NR	NR	2	0.494	0.157	1	0.915	0.202
Ischemic heart disease (SMQ)	373	1.802	1.653	253	1.85	1.667	494	1.16	1.077	177	1.896	1.673
Myocardial infarction (SMQ)	325	1.912	1.744	229	2.016	1.806	430	1.22	1.126	161	2.08	1.824
CNS hemorrhages and cerebrovascular conditions (SMQ)	154	0.911	0.796	75	0.594	0.49	297	0.78	0.708	70	0.876	0.717
Event*	Second-generation PIs											
	Atazanavir			Darunavir			Fosamprenavir			Tipranavir		
	<i>n</i>	EBGM	EB05	<i>n</i>	EBGM	EB05	<i>n</i>	EBGM	EB05	<i>n</i>	EBGM	EB05
Carotid artery occlusion	NR	NR	NR	NR	NR	NR	1	1.082	0.238	NR	NR	NR
Carotid artery stenosis	NR	NR	NR	NR	NR	NR	NR	NR	NR	3	2.829	1.063
Carotid artery thrombosis	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Coronary artery insufficiency	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
Coronary artery occlusion	5	0.577	0.272	6	1.192	0.598	2	0.86	0.272	1	0.75	0.165
Coronary artery thrombosis	5	1.914	0.901	NR	NR	NR	NR	NR	NR	NR	NR	NR
Coronary artery stenosis	10	2.189	1.282	4	1.732	0.749	3	1.761	0.675	NR	NR	NR
Ischemic stroke	NR	NR	NR	3	0.744	0.285	NR	NR	NR	NR	NR	NR
Sudden cardiac death	6	1.919	0.963	2	0.912	0.289	NR	NR	NR	NR	NR	NR
Ischemic heart disease (SMQ)	176	0.881	0.777	140	1.112	0.966	37	0.884	0.671	8	0.382	0.21
Myocardial infarction (SMQ)	149	0.894	0.78	121	1.169	1.005	33	0.929	0.693	6	0.335	0.168
CNS hemorrhages and cerebrovascular conditions (SMQ)	102	0.565	0.479	93	0.793	0.667	24	0.679	0.482	29	1.585	1.159

The threshold for disproportional reporting was $n \geq 3$, $EBGM \geq 2$, and $EB05 > 1$. Events that met the disproportionality threshold are in bold 2016Q2 2016 quarter 2, *CI* confidence interval, *CNS* central nervous system, *FAERS* US Food and Drug Administration Adverse Event Reporting System, *EBGM* Empirical Bayesian Geometric Mean, *EB05* lower bound of the 2-sided 90% CI around EBGM, *MedDRA* Medical Dictionary for Regulatory Activities, *NR* not reported, *PIs* protease inhibitors, *SMQ* Standardized MedDRA Query

*Events based on MedDRA preferred terms or SMQs (as noted)

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium,

provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.